-- Company Announces Formation of Board of Directors

FibroBiologics, a clinical stage company developing fibroblast-based 
therapeutic solutions for chronic diseases, announced today the formation of 
its Board of Directors.  Leading this group is Chairman, Pete O'Heeron along 
with members Rich Cilento, Stacy Coen, Robert Hoffman, Matthew Link, and 
Victoria Niklas, MD.

Logo - https://mma.prnewswire.com/media/1588786/FibroBiologics_Logo.jpg

"As we pursue accelerated development of our clinical programs in degenerative 
disc disease, orthopedics, multiple sclerosis and cancer, we are fortunate to 
attract highly respected industry leaders to our mission," stated Pete 
O'Heeron, Chairman/Founder/CEO. "Our Board comprises a broad range of talented 
executives with experiences across the entire biotech community. Their 
leadership will guide us through the development, regulatory, and 
commercialization processes in an effort to bring these life-changing therapies 
to suffering patients."

FibroBiologics Board Members include:

Rich Cilento, MBA – Chairman & CEO of GlycosBio, Inc., Entrepreneur

Stacy Coen, MBA – SVP, Chief Business Officer of Immunogen, Inc., Board Trustee 
of Huntington's Disease Society of America (HDSA)

Robert Hoffman, CPA – Chairman of Kintara Therapeutics and Board Member of 
ASLAN Pharmaceuticals and Antibe Therapeutics

Matthew Link, BSEd – Managing Director Orion Healthcare Advisors, Former 
President NuVasive

Victoria Niklas, MD – Vice President, Global Program Leader R&D Plasma-Derived 
Therapies Unit, Takeda Pharmaceuticals

Pete O'Heeron, MSHA – Chairman/Founder/CEO FibroBiologics, University of 
Chicago, University of Houston-CL, Texas State University

For more in-depth biographies on individual Board members, please visit our 
website: https://www.fibrobiologics.com/team/#board

About FibroBiologics

Based in Houston, Texas, FibroBiologics is a regenerative medicine company 
developing an innovative solution for chronic disease treatment using 
fibroblast cells. Currently, FibroBiologics holds 150+ U.S. and International 
issued patents/patents pending across a variety of clinical pathways, including 
Disc Degeneration, Orthopedics, Multiple Sclerosis, and Cancer. FibroBiologics 
represents the next generation of medical advancement in cell therapy.

Visit: www.FibroBiologics.com

SOURCE: FibroBiologics